Bayer (BAYN) Given a €77.00 Price Target by Goldman Sachs Group Analysts

Goldman Sachs Group set a €77.00 ($89.53) price objective on Bayer (FRA:BAYN) in a report released on Tuesday morning, Borsen Zeitung reports. The firm currently has a buy rating on the healthcare company’s stock.

Several other equities research analysts have also commented on the stock. Baader Bank set a €123.00 ($143.02) price objective on shares of Bayer and gave the stock a buy rating in a research report on Tuesday. Sanford C. Bernstein set a €89.00 ($103.49) price objective on shares of Bayer and gave the stock a buy rating in a research report on Tuesday. JPMorgan Chase & Co. set a €70.00 ($81.40) price objective on shares of Bayer and gave the stock a neutral rating in a research report on Tuesday. Warburg Research set a €61.00 ($70.93) price objective on shares of Bayer and gave the stock a neutral rating in a research report on Wednesday, May 1st. Finally, Barclays set a €85.00 ($98.84) price objective on shares of Bayer and gave the stock a buy rating in a research report on Friday, April 26th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have issued a buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of €81.67 ($94.97).

Bayer stock opened at €57.01 ($66.29) on Tuesday. Bayer has a 52 week low of €91.58 ($106.49) and a 52 week high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Story: Asset Allocation, Balancing Your Investments

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.